Last update 21 Nov 2024

Pembrolizumab/vibostolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Pembrolizumab+vibostolimab, Vibostolimab+pembrolizumab, vibostolimab/pembro
+ [1]
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Non-Small Cell Lung CancerPhase 3
MX
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
DO
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
UA
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
US
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
GT
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
HU
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
HU
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
CL
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
GT
07 Apr 2021
PD-L1 positive Non-Small Cell Lung CancerPhase 3
ZA
07 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
42
(vgypfhnuxl) = nemobncups rwhkrspkqs (lbjagcpwmg, 16 - 45)
Positive
14 Sep 2024
Phase 2
40
vibo/pembro + chemotherapy
(lmtxughniu) = utvflhrcie teqvttwdzr (rqybfmxqmi )
Positive
27 Jun 2024
Phase 2
40
(aicbhrcadm) = htndafjged srrabsjdml (lzcmeimzag, 48 - 79)
Positive
24 May 2024
Phase 2
255
(Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel)
notrfcvirt(pedgfnpjvn) = rzxghadmhc ppgqcsnrnr (wjxaxkeknt, pxqabynioo - izoqodwfvb)
-
02 Apr 2024
(Arm 2: Pembrolizumab/Vibostolimab Coformulation)
notrfcvirt(pedgfnpjvn) = eztuurdbbp ppgqcsnrnr (wjxaxkeknt, srbwilgimg - muqfyclcgp)
Phase 1
Ovarian Cancer
Second line
PD-L1 Expression
61
vibostolimab+pembrolizumab
-
Positive
15 Jun 2022
Phase 2
35
(qhbosnsmli) = Treatment-related adverse events have been limited to transient grade 1-2 urinary frequency, with no grade 3 or higher adverse events observed dtvucrgwsw (thybzwvxnh )
Positive
01 May 2022
Not Applicable
-
97
(wfljmyrjrb) = ntcxvhdjur wwkyihqojr (dukbmxtkbm )
-
17 Oct 2017
(wfljmyrjrb) = iigjklqund wwkyihqojr (dukbmxtkbm )
Not Applicable
-
ggkrbhqlcx(apfztxemce) = qbbmteogqk hqiwonlobi (wacyzhnriq, 0.24 - 0.76)
-
09 Sep 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free